Search Results for “ breast cancer” – Page 28 – media

Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal

Two months after expanding a licensing deal with Genentech, privately-held Arvinas LLC struck another lucrative deal with a major pharmaceutical company. Connecticut-based Arvinas inked a deal with Pfizer worth up to $830 million to develop small molecules that can degrade proteins.
- Source: Biospace
- 526
- January 8, 2018
Genentech Pfizer pharmaceutical company PROTAC small molecule therapeutics
After disappointing 2016, new drug approvals roared back to life in 2017

New drug approvals all but screeched to a halt in 2016, with a measly 22 new OKs after a pair of bountiful years. But the FDA wasted no time in 2017, signing off on 12 drugs in the first quarter alone—besting its record for the same period of any year in recent history.
- Source: fiercebiotech
- 623
- January 4, 2018
CAR-T therapy FDA New Approvals new drug
Nanoparticle-Based Imaging of Metastasis Throughout Body

Cancer cells can lodge in different niches in the body, and the probe follows the spreading cells wherever they go
- Source: medgadget
- 866
- December 20, 2017
breast cancer MRI Researches tumor
Novartis-backed resTORbio raises $40M for aging disease trials

Boston biotech resTORbio has pocketed another $40 million from a second-round financing that it hopes gives it enough cash to move its lead candidate for respiratory tract infections in elderly patients into phase 3.
- Source: Fiercebiotech
- 619
- December 19, 2017
financing immune system Market Views Novartis
Pfizer and Genentech Duke it Out in Court Over Herceptin Biosimilar Patents

On Friday, November 17, Genentech, a Roche company, sued Pfizer in a federal court in Wilmington, Delaware, over Pfizer’s biosimilar for Genentech’s Herceptin. Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Genentech also is demanding compensation for lost sales if Pfizer launches its copycat version before the Herceptin patents expire.
- Source: Biospace
- 644
- November 24, 2017
biosimilar Company Insight FDA Genentech herceptin Pfizer Roche
China’s Import and Export Report of Antineoplastic Drugs

Antineoplastic or anticancer drugs, affect the process of cell division i.e. are antiproliferative. They damage the DNA and initiate apoptosis, preventing the development and spread of neoplastic cells. Commonly used antineoplastic drugs can be divided into the following six categories: alkylating agents, anti-metabolites, anticancerous, antibiaties, aminoglutethimide and others. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, shares China’s Import and Export Report of Antineoplastic Drugs with you. General situation of global market of antineoplastic drugs According to the IMS’s latest report, “Global Oncology Trends 2017” showed that in 2016 the global market sales of antineoplastic drugs were 89.6 billion USD and 85 billion USD in 2015. Over the past five years, the global market of antineoplastic drugs has grown at a compound annual growth rate (CAGR) of 8.7% and is expected to exceed 147 billion USD by 2021. As indicated on the chart, the United States, the European Union and Japan are still the driving ...
- Source: Ddu
- 1,498
- November 3, 2017
anticancer Antineoplastic Market Reports neoplastic cells
Roche reports strong performance in the first half of 2017

Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
- Source: www.roche.com
- 512
- August 4, 2017
Company Insight
Tumor-targeting MRI contrast developed, based on human protein

A team led by Gang Han, PhD, has designed a human protein-based, tumor-targeting Magnetic Resonance Imaging (MRI) contrast that can be easily cleared by the body. The discovery holds promise for clinical application, including early stage tumor detection because of the enhanced MRI contrast, according to Dr. Han, associate professor of biochemistry & molecular pharmacology at University of Massachusetts Medical School.
- Source: drugdu
- 424
- July 7, 2017
breast cancer Clinical New Approvals tumor
Baird Medical’ successfully went public in the United States

Recently, Baird Medical’s business merger with overseas special purpose acquisition company ExcelFin Acquisition Corp. has been approved by the US SEC, and the F-4 application documents have officially come into effect, with a declaration of registration effectiveness issued. Baird Medicalhas achieved listing on the NASDAQ Stock Exchange in the United States through the merger with ExcelFin Acquisition Corp., a foreign special purpose acquisition company. In addition, Baird Medicalalso announced that ExcelFin has arranged a special shareholders’ meeting to be held on September 26, 2024. After the meeting, it is expected to receive approval from ExcelFin shareholders and the merger will be completed soon. The bumpy road falls on the eve of going public Before going public in the United States, Baird Medicalhad a bumpy road to going public in Hong Kong. Founded in 2012, Baird Medicalis a leading developer and provider of microwave ablation medical devices for minimally invasive treatment ...
- Source: drugdu
- 59
- September 14, 2024
Avzivi® (BAT1706) receives marketing approval from European Commission

BIO-THERA Biopharmaceutical Co., Ltd (SSE: 688177) is a global science-based and innovative biopharmaceutical company based in Guangzhou, China, hereinafter referred to as “BIO-THERA” or the “Company”. The Company is dedicated to the development of a new generation of innovative drugs and biosimilars for the treatment of oncology, autoimmune diseases, cardiovascular diseases, ophthalmology, and other major diseases that threaten human life or health. The Company recently received notification from the European Commission that Avzivi (BAT1706), a biosimilar developed by BIO-THERA with reference to Avastin® (bevacizumab), Intravenous Solution, has been granted marketing authorization by the European Commission for the treatment of metastatic colorectal, metastatic breast, non-small-cell lung, renal-cell, epithelial ovarian, fallopian tube or primary peritoneal, and cervical cancer. The decision was based on a positive review opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). In September 2021, BIO-THERA signed a commercialization and license ...
- Source: drugdu
- 81
- August 1, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.